Anzeige
Mehr »
Samstag, 09.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EMJR | ISIN: US45719W2052 | Ticker-Symbol: IQT0
NASDAQ
08.08.25 | 21:49
1,425 US-Dollar
-9,24 % -0,145
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INHIBIKASE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
INHIBIKASE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur INHIBIKASE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.06.Inhibikase Therapeutics, Inc. - 8-K, Current Report1
20.06.Inhibikase Therapeutics files $300M mixed securities shelf1
INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln
14.05.Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report2
14.05.Inhibikase Therapeutics, Inc. - 8-K, Current Report2
12.05.Former Inhibikase leader launches new biotech for midstage Parkinson's asset1
14.04.Inhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-market-
14.04.Inhibikase Therapeutics appoints new CFO2
14.04.Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise1
14.04.Inhibikase Therapeutics, Inc. - 8-K, Current Report2
31.03.H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock3
27.03.Inhibikase Therapeutics GAAP EPS of -$1.161
27.03.Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
27.03.Inhibikase Therapeutics, Inc. - 10-K, Annual Report1
27.03.Inhibikase Therapeutics, Inc. - 8-K, Current Report1
27.03.Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity436BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor...
► Artikel lesen
24.02.Inhibikase enhances leadership with new appointments1
18.02.Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth201-- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON...
► Artikel lesen
18.02.Inhibikase Therapeutics, Inc. - 8-K, Current Report-
14.11.24Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity221-- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial...
► Artikel lesen
21.10.24Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension248-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1